Avanos Medical, Inc.
Avanos Medical, Inc. (AVNS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
avns · stock forecast · 8 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 8 Wall Street analysts in the past 3 months
Hold
8 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$26.00
Consensus
$23.00
-8.0% upside
Low
$20.00
Median: $23 · Last Close: $25.01
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$23.00
-8.0% upside
High Target
$26
4.0%
Low Target
$20
-20.0%
Current Price
$25.01
as of today
Based on analyst price targets, the AVNS stock price prediction for the next 12 months ranges from $20 to $26. The consensus AVNS price forecast of $23.00 implies -8.0% upside from the current price of $25.01.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $25.09 | ↑ 0.33% |
1-day model range: $25.08–$25.1. Peak: $25.1 (+0.33%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · AVNS · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-07-25 | Keybanc | Downgrade ↓ | Overweight→Sector Weight |
| 2023-06-21 | Stifel | Maintains | Hold→Hold |
| 2023-05-04 | Morgan Stanley | Maintains | Underweight→Underweight |
| 2023-02-22 | Morgan Stanley | Maintains | Underweight→Underweight |
| 2023-01-06 | Morgan Stanley | Maintains | Underweight→Underweight |
| 2022-11-03 | Keybanc | Maintains | Overweight→Overweight |
| 2022-10-11 | Morgan Stanley | Maintains | Underweight→Underweight |
| 2022-08-10 | Keybanc | Maintains | Overweight→Overweight |
| 2022-07-18 | Stifel | Maintains | Hold→Hold |
| 2022-07-15 | Morgan Stanley | Maintains | Underweight→Underweight |
Wall Street analysts have recently issued updated ratings on Avanos Medical, Inc. (AVNS) stock. Of the recent 47 rating actions, 2 were upgrades and 6 were downgrades. 8 analysts currently cover AVNS.
Analyst Recommendation Trends
AVNS analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$682M
↓ 1.8% YoY
Revenue Next Year
$685M
↑ 0.4% YoY
EPS This Year
$0.00
EPS Next Year
$1.32
EPS ForecastReported vs Estimated
Analysts forecast AVNS EPS of $0.00 for the current fiscal year, based on estimates from 0 analysts. The AVNS revenue forecast is $682M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The AVNS stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AVNS price target is $23.00 (-8.0% upside), with an analyst consensus of Hold.
The AVNS short-term stock prediction for tomorrow is $25.09 (+0.33%).
Avanos Medical, Inc. trades on NYSE under the ticker AVNS. The AVNS stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 13% of covering analysts.
Frequently asked questions
AVNS forecast · 8 questionsAccording to 8 Wall Street analysts, the average 12-month AVNS price target is $23.00, with a high forecast of $26.00 and a low of $20.00. The median price target is shown in the chart above when available. This implies -8.0% potential upside from the current price of $25.01.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.